Difficulty: Medium
Average Score: 62%
Practice
A 9-year-old boy develops acute myelogenous leukemia (AML) one year after completion of therapy for soft tissue sarcoma at his right thigh. Which of the following chemotherapeutic agents is MOST likely the cause of secondary acute myelogenous leukemia AML in this boy?
Correct answer
C
Rationale
In this scenario, the correct answer is C) etoposide. Etoposide is known to have the potential to cause secondary AML as a late effect of cancer therapy. This is due to its ability to induce chromosomal translocations and gene mutations that can lead to the development of secondary malignancies like AML.
A) Cyclophosphamide is commonly used in chemotherapy regimens but is not typically associated with secondary AML as much as etoposide.
B) Vincristine is a vinca alkaloid that is more commonly associated with peripheral neuropathy rather than secondary AML.
D) Doxorubicin is an anthracycline that is known for cardiotoxicity rather than causing secondary AML.
It is essential for healthcare providers to be aware of the potential long-term side effects of chemotherapeutic agents in pediatric patients to monitor and manage their care effectively. Understanding the specific risks associated with each drug helps in making informed decisions regarding treatment and follow-up care.
A) Cyclophosphamide is commonly used in chemotherapy regimens but is not typically associated with secondary AML as much as etoposide.
B) Vincristine is a vinca alkaloid that is more commonly associated with peripheral neuropathy rather than secondary AML.
D) Doxorubicin is an anthracycline that is known for cardiotoxicity rather than causing secondary AML.
It is essential for healthcare providers to be aware of the potential long-term side effects of chemotherapeutic agents in pediatric patients to monitor and manage their care effectively. Understanding the specific risks associated with each drug helps in making informed decisions regarding treatment and follow-up care.